Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a biopharmaceutical company headquartered in Edison, New Jersey. Founded in 2013, the company focuses on developing advanced drug therapies for chronic liver diseases. Hepion's core mission is to enhance treatment options for liver conditions such as non-alcoholic steatohepatitis (NASH), viral hepatitis, and hepatocellular carcinoma (HCC).
The company's flagship product is Rencofilstat, a pan-cyclophilin inhibitor designed to target multiple pathological pathways involved in liver disease progression. This pleiotropic drug therapy has shown promising results in preclinical and clinical trials, including recently completed Phase I trials. Rencofilstat is currently being studied for its potential to address complex liver pathologies, including fibrosis and cancerous conditions associated with NASH and hepatitis.
Another significant development from Hepion is Tenofovir Exalidex, a lipid acyclic nucleoside phosphonate intended to deliver high intracellular concentrations of tenofovir diphosphate, an active antiviral agent. This drug aims to offer more effective treatment options for Hepatitis B patients.
Hepion Pharmaceuticals has also made headlines with its adoption of artificial intelligence (AI)-driven drug development, focusing on precision medicine for chronic diseases. Recent research has revealed that Rencofilstat may exert anti-cancer activity through mechanisms such as altering DNA accessibility, silencing oncogenes, and activating tumor suppressor genes.
The company was formerly known as ContraVir Pharmaceuticals, Inc. before rebranding to Hepion Pharmaceuticals in July 2019 to better align with its focus on liver disease therapies. With a commitment to cutting-edge research and development, Hepion Pharmaceuticals continues to advance its clinical programs and partnerships, offering hope to patients suffering from debilitating liver diseases.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) has appointed Anand Reddi and Kaouthar Lbiati to its Board of Directors. Reddi brings extensive experience in corporate strategy and drug development, while Lbiati has a strong background in global health policy and oncology. These appointments come as Hepion prepares to advance its lead drug candidate, rencofilstat, into three Phase 2 clinical trials, targeting NASH and hepatocellular carcinoma. Hepion has previously received FDA Fast Track and Orphan Drug designations for rencofilstat, highlighting its potential in treating these chronic diseases.
Hepion Pharmaceuticals (NASDAQ:HEPA) has adjourned its 2022 annual meeting to July 22, 2022, mainly concerning Proposal 4 (Authorized Share Increase). Votes representing about 60% of outstanding shares constituted a quorum. While elections for directors and the appointment of independent auditors passed, Proposals 3 (2022 Omnibus Equity Incentive Plan), 4 (Authorized Share Increase), and 5 (Say-On-Pay) did not receive sufficient support. The Board urges stockholders to vote for Proposal 4, emphasizing the necessity for additional shares for corporate flexibility, including future financings and acquisitions.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced FDA's Orphan Drug Designation for its drug rencofilstat, aimed at treating hepatocellular carcinoma (HCC). This designation highlights its potential to address significant unmet medical needs in an aggressive cancer type, which accounts for 85-90% of liver cancer cases. Hepion plans to initiate a Phase 2a study of rencofilstat in HCC in Q3 2022, alongside ongoing Phase 2 studies for non-alcoholic steatohepatitis (NASH). The Orphan Drug Designation offers various incentives, including potential seven-year market exclusivity and tax credits for clinical trials.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced that five abstracts were accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, held from June 22 to 26, 2022, in London. These presentations focus on rencofilstat, a cyclophilin inhibitor in clinical development for non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Key topics include its anti-tumor activities and anti-fibrotic effects demonstrated in clinical trials.
Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Dr. Launa J. Aspeslet as Chief Operating Officer to bolster the clinical program for its lead candidate, rencofilstat. Dr. Aspeslet brings over 25 years of experience from her previous role as CEO of Translational Research in Oncology and significant contributions at Isotechnika Pharma. She joins Hepion after the company reported positive Phase 2a results and is preparing for three additional Phase 2 studies targeting non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). This leadership change aims to enhance strategic development.
Hepion Pharmaceuticals (NASDAQ:HEPA) encourages stockholders to vote 'FOR' all proposals ahead of the June 24, 2022, Annual Meeting. CEO Dr. Robert Foster highlighted the biotech sector's decline, necessitating shareholder support to advance their lead drug, rencofilstat, for NASH and HCC. Hepion prepares for three Phase 2 clinical trials of rencofilstat, expecting patient enrollment to start in Q3 2022. Approval of the 2022 Omnibus Equity Incentive Plan is critical to attract talent and resolve a current share issue, while a change in authorized shares is vital for future financing.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the presentation of positive data from its Phase 2a ‘AMBITION’ NASH clinical trial at the 5th Global NASH Congress. Chief Medical Officer Todd Hobbs discussed upcoming trials for rencofilstat, focusing on three new studies: ASCEND-NASH, ALTITUDE-NASH, and HEPA-CRV431-209, all set to begin enrollment in Q3 2022. The company sees significant potential for rencofilstat in treating NASH and HCC, with FDA Fast Track designation already granted. The proprietary AI platform, AI-POWR™, will assist in identifying effective treatments for patients.
Hepion Pharmaceuticals (NASDAQ:HEPA) has launched a Phase 2b clinical trial to evaluate the efficacy of rencofilstat in treating non-alcoholic steatohepatitis (NASH) using the innovative HepQuant SHUNT test. This trial aims to assess liver function in 60 presumed NASH F3 subjects over four months. The SHUNT test promises to provide sensitive measurements that could replace invasive liver biopsies. Concurrently, Hepion will conduct a larger 12-month biopsy trial, enhancing its understanding of rencofilstat's impact on liver health. The FDA previously granted Fast Track designation to rencofilstat for NASH treatment.
Hepion Pharmaceuticals (NASDAQ: HEPA) announced that Dr. Todd Hobbs, its CMO, will present at the Q1 Investor Summit Conference on March 9, 2022, at 1:15 p.m. ET. The presentation will be accessible live and archived on their website. Hepion's lead candidate, rencofilstat, is a potent cyclophilin inhibitor currently under clinical development for non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The FDA granted Fast Track designation for rencofilstat for NASH in November 2021, with an IND application for HCC accepted in December 2021.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
What is the main focus of Hepion Pharmaceuticals?
What is Rencofilstat?
What other products is Hepion Pharmaceuticals developing?
Where is Hepion Pharmaceuticals headquartered?
When was Hepion Pharmaceuticals founded?
Has Rencofilstat completed any clinical trials?
Does Hepion Pharmaceuticals use any advanced technologies in its research?
What was the former name of Hepion Pharmaceuticals?
Why did the company change its name?
Is Hepion Pharmaceuticals involved in any partnerships?
